Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInfectious Agent Antigen DetectionCPT cpt-87564-mycobacterium-tuberculosis-rifampin-resistance-test
    Ask Trek AI about this page

    CPT 87564: Mycobacterium tuberculosis Amplified Nucleic Acid Test with Rifampin Resistance

    CPT code 87564 describes a laboratory nucleic acid amplification test for Mycobacterium tuberculosis, performed by a lab analyst using an amplified nucleic acid probe technique that also detects rifampin resistance; service type is molecular infectious disease testing and the typical site of service is a clinical laboratory or hospital laboratory where microbiology and molecular diagnostics are performed.

    For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.

    Customize your policy alerts

    Sign up for cpt 87564 policy alerts

    Get alerted when payer policies referencing 87564 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 52-year-old patient presents to an outpatient infectious disease clinic with a two-week history of persistent cough, night sweats, weight loss, and a recent positive chest radiograph showing upper lobe cavitary changes. A sputum specimen is collected and sent to the microbiology laboratory for molecular testing to detect Mycobacterium tuberculosis complex and assess rifampin resistance. The laboratory technologist performs an amplified nucleic acid probe assay that targets MTB nucleic acid and includes detection of the rpoB gene mutation associated with rifampin resistance. Results are reported to the ordering clinician and the public health department when required. Typical workflow steps: specimen collection (sputum or bronchoalveolar lavage), specimen transport to the molecular laboratory, nucleic acid extraction, amplification and probe hybridization, result interpretation, and reporting. Typical site of service is a hospital laboratory, freestanding clinical laboratory, or large outpatient microbiology laboratory performing molecular diagnostic testing.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    87481Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, amplified probe technique, direct probe techniqueAlternative molecular methods for MTB detection sometimes used in parallel or by different labs; may be performed when assay platforms differ.
    87015Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolatesMycobacterial culture is commonly ordered alongside molecular testing to obtain viable organisms for drug susceptibility testing and confirmation.
    87116Culture, mycobacterial, any source, with identification when performedSpecific mycobacterial culture and identification complements molecular detection and allows full susceptibility testing.
    87899Unlisted infectious agent detection procedure, by nucleic acid (DNA or RNA)Used for novel or specialized molecular assays for TB or resistance markers not represented by a specific code.
    87476Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, amplified probe techniqueExample of other respiratory pathogen molecular tests that may be ordered in the differential diagnostic workup of atypical pneumonia alongside MTB testing.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    23Modifier -23 (Unusual Anesthesia) is used on anesthesia service CPT codes when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia…- Use modifier -23 only on anesthesia CPT codes (00100–01999) when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia because of…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    208000000X
    207Q00000X
    363L00000X
    222Q00000X
    261QR0206X
    311500000X
    2279E0002X
    156FX1201X

    Related ICD-10-CM Codes

    23 rows

    ICD-10-CM CodeDescription
    A15.0Tuberculosis of lung
    A15.9Respiratory tuberculosis unspecified
    A17.0Tuberculous meningitis
    A17.9Tuberculosis of nervous system, unspecified
    A31.0Pulmonary mycobacterial infection
    A31.9Mycobacterial infection, unspecified
    B59Pneumocystosis
    F03.90Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
    J15.9Unspecified bacterial pneumonia
    J18.9Pneumonia, unspecified organism

    Showing 1–10 of 23

    Related Payer Policy Updates

    Specialty: Infectious Disease1 / 3

    10 rows

    PolicyPayerEffective Date
    Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    HIV/AIDS Pharmacologic Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    Long-Acting Injectable Antiretroviral Agents for HIVColorado Rocky Mountain Health Plans2026-10-01
    B-Hemolytic Streptococcus TestingOscar Health2026-10-01
    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance AssaysOscar Health2026-10-01
    Hepatitis Testing (A, B, C, D) Coverage CriteriaOscar Health2026-10-01
    Pathogen Panel TestingOscar Health2026-10-01
    Lyme Disease Testing Coverage CriteriaOscar Health2026-10-01
    Diagnostic Testing of Common Sexually Transmitted InfectionsOscar Health2026-10-01
    Testing for Diagnosis of Active or Latent TuberculosisOscar Health2026-10-01

    Related Codes

    CPT-87260-ADENOVIRUS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87260: Adenovirus Antigen Detection by Immunofluorescence

    CPT-87265-BORDETELLA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87265: Bordetella Antigen Detection by Immunofluorescence

    CPT-87267-ENTEROVIRUS-DFA-ANTIGEN-DETECTION

    CPT 87267: Enterovirus Antigen Detection by DFA

    CPT-87269-GIARDIA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87269: Giardia Antigen Detection by Immunofluorescence

    CPT-87270-CHLAMYDIA-TRACHOMATIS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87270: Chlamydia trachomatis Antigen Detection by Immunofluorescence

    CPT-87271-CMV-DFA-ANTIGEN-DETECTION

    CPT 87271: CMV Antigen Detection by Direct Fluorescent Antibody

    CPT-87272-CRYPTOSPORIDIUM-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87272: Cryptosporidium Antigen Immunofluorescent Test

    CPT-87273-HSV-2-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87273: HSV-2 Antigen Detection by Immunofluorescence

    CPT-87274-HSV-1-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87274: HSV-1 Antigen Detection by Immunofluorescence

    CPT-87275-INFLUENZA-B-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87275: Influenza B Antigen Detection by Immunofluorescence

    Showing 1–10 of 167

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.